


FORM PTO-1449		U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.		SERIAL NO.	
				U013469-7		09/856,282	
				APPLICANT			
				BONNIE M. DAVIS			
				FILING DATE		GROUP	
				June 18, 2001		1614	
 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)							
U.S. PATENT DOCUMENTS							
EXAMINER INITIALS	REFERENCE DESIGNATION	DOCUMENT NUMBER	DATE	NAME		FILING DATE IF APPROPRIATE	
	AA						
	AB						
	AC						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	AD						
	AE						
	AF						
OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.)							
AM	AG	Circadian Rhythms and Drug Deliver - Journal of Controlled Release, 16 (1991) 63-74					
AM	AH	Sensitive Liquid Chromatographic Method for Physostigmine in biological fluids using dual-electrode electrochemical Detection - Robin Whelpton & Thomas Moore - Journal of Chromatography 341 (1985) 361-371					
	AI	Physician Desk Reference, Antiven, Pfizer/2665-2667					
	AJ	A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patient - R. C. Mohs, PhD, Neurology 57 - pgs.481-486					
	AK	Psychotropics Terminal Plasma half lives - Eptastigmine tartrate					
	AL	Psychotropics Terminal Plasma half lives - Tacrine					
AM	AM	Pub Med - J. Clin Pharmacol, 1989 Mar 29(3) 278-84 - Single dose safety, tolerance and pharmacokinetics of HP 092 in healthy young men: a potential Alzheimer agent - Pur SK, Hsu RS, Ho I, Lassman HB					
AM	AN	Pub Med - J. Clin Pharmacol, 1990 Oct 30(10) 948-55 - Multiple dose pharmacokinetics, safety, and tolerance of velnarine (HP029) in healthy elderly subjects: a potential therapeutic agent for Alzheimer's disease - Puri SK, Ho I, Hsu R, Lassman HB					
AM	AO	Pub Med - Expert Opin Investig Drugs 1999 Apr 8(4) 463-71-Metirfonate (Trichlorfon): a review of the pharmacology, pharmacokinetics and clinical experience with a new acetylcholinesterase inhibitor for Alzheimer's disease. - Ringman JM, Cummings, JL					
EXAMINER		Arden Marshall			DATE CONSIDERED 4/5/07		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

No Pub.
date

FORM PTO-1449 U. S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		ATTY. DOCKET NO.		SERIAL NO.	
		U013469-7		09/856,282	
		APPLICANT			
		BONNIE M. DAVIS			
		FILING DATE		GROUP	
		June 18, 2001		1614	
U.S. PATENT DOCUMENTS					
EXAMINER INITIALS	REFERENCE DESIGNATION	DOCUMENT NUMBER	DATE	NAME	FILING DATE IF APPROPRIATE
	AA				
	AB				
	AC				
FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
					YES NO
	AD				
	AE				
	AF				
OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.)					
	AG	Razadyne galantamine HBr - pgs 1-6			
	AH	Fluoride Action Network Pesticide Project Adverse Effects methanesulfonyl fluoride - Cas No. 558-25-8			
	AI	Calbiochem - Phenylmethylsulfonyl Fluoride - Cat. No. 52332			
AM	AJ	Pub Med. J. Microencapsul. 2005 Feb 22(1) 57-66 - Effects of formulation factors on encapsulation efficiency and release behaviour in vitro of huperzine A-PLGA microspheres - Fu X, Ping Q, Gao Y			
	AK	GPnotebook - Endrophonium test			
	AL	Effects of Novel Cholinesterase inhibitors based on the mechanism of enzyme inhibition - Albert Enz, Dieter Meier and Rene Spiegel			
AM	AM	Journal of Chromatography 272 (1983) 216-220 - Analysis of plasma physostigmine concentrations by liquid chromatography - Robin Whelpton			
AM	AN	Arch Neurol/vol 58, Mar 2001 - Open-Label, Multicenter, phase 3 extension study of the safety and Efficacy of Donepezil in Patients with Alzheimer Disease - Rachelle S. Doody MD -p. 427-433			
AM	AO	The Effects of Donepezil in Alzheimer's Disease-Results from a Multinational Trial - Derment Geriatr Cogn Disord 1999; 10: 237-244 - A. Burns			
EXAMINER <i>John Manalich</i>			DATE CONSIDERED <i>4/5/07</i>		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449 U. S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		ATTY. DOCKET NO.		SERIAL NO.	
		U013469-7		09/856,282	
		APPLICANT			
		BONNIE M. DAVIS			
		FILING DATE		GROUP	
		June 18, 2001		1614	
U.S. PATENT DOCUMENTS					
EXAMINER INITIALS	REFERENCE DESIGNATION	DOCUMENT NUMBER	DATE	NAME	FILING DATE IF APPROPRIATE
	AA				
	AB				
	AC				
FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
					YES NO
	AD				
	AE				
	AF				
OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.)					
AM	AG	International Journal of Chronobiology, Vol. 2, 281-289 (1974) - Circadian Variations of Acetylcholinesterase (E.C.3.1.1.7) in Rats Brains O H. Schiebeler and H. v. Mayersbach			
AM	AH	Neuroscience Letters 300 (2001) 157-160 - Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease - Pia Davidsson			
AM	AI	Brain Research, 122 (1977) 562-267 - The time-dependent induction of REM sleep and arousal by physostigmine infusion during normal human sleep - Natarajan Sitaram			
AM	AJ	JAGS - Jan. 1998 - Vol. 46, No. - p. 119-120-Aricept-induced nightmares in Alzheimer's Disease			
	AK				
	AL				
	AM				
	AN				
	AO				
EXAMINER	Adam Mancoske		DATE CONSIDERED 4/5/07		
EXAMINER:	Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				